Texas AG promises investigation into Big Pharma pushing puberty blockers on children
12/20/2021 / By Ethan Huff
Attorney General Ken Paxton of Texas is launching an investigation into two pharmaceutical companies that are accused of violating the Texas Deceptive Trade Practices Act by promoting puberty blockers for children on the pathway to becoming transgender.
Paxton is focusing on Endo Pharmaceuticals, Inc., and AbbVie Inc., both of which allegedly advertised and promoted hormone (puberty) blockers for unapproved uses while failing to disclose the potential risks involved with taking them.
Currently, medications like Supprelin LA and Lupron Depot are approved by the U.S. Food and Drug Administration (FDA) to treat children with Central Precocious Puberty, or CPP, a condition in which the puberty process begins prematurely.
Vantas, along with other forms of Lupron, can also be prescribed for the palliative treatment of prostate cancer, another hormone-driven disease.
Ever since the LGBTQ mafia started aggressively pushing children to become “trans,” however, drug giants have allegedly been promoting the aforementioned drugs to treat “gender dysphoria,” even though the FDA has never approved them for this purpose.
Gender dysphoria is a diagnosed mental disorder, just to be clear. It requires a different kind of treatment in order to get rid of it, not the prescription of gender-bender drugs that affirm it as normal and recreate a person’s body in the image of the opposite sex.
“The manufacture, sale, prescription, and use of puberty blockers on young teens and minors is dangerous and reckless,” Paxton said.
“These drugs were approved for very different purposes and can have detrimental and even irreversible side effects. I will not allow pharmaceutical companies to take advantage of Texas children.”
Parents: Protect your children from life-destroying gender-bender drugs
In a statement to Fox News, Endo Pharmaceuticals denied ever promoting its gender-bender drugs for gender dysphoria.
“The company has not promoted either of these medications outside of their indications and does not promote medications for off-label uses,” said Heather Zoumas Lubeski, a company spokesperson. “That being said, we intend to fully cooperate with this inquiry / investigation.”
“We do not have any approved medications indicated for gender dysphoria and we do not promote medications for off-label uses,” she further added.
AbbVie reportedly did not respond to a request for comment by press time.
Dr. Michael Laidlaw, an independent private practice endocrinologist in Rocklin, Calif., told Fox that he fully agrees with AG Paxton’s investigation.
“I agree with AG Paxton that these drugs are only FDA approved as puberty blockers in children for the purpose of treating central precocious puberty and not for gender dysphoria,” he said.
“Central precocious puberty is a medical condition in which a child starts puberty at an abnormally young age, say age four. Medications like Supprelin LA are used to stop this abnormal puberty. Then once the child reaches a typical age for puberty (say age 11 or 12), the medication is stopped, and then normal puberty will resume.”
Using such drugs for off-label purposes, including to treat gender dysphoria, is a “completely different” thing, he added, that is not appropriate for older children who are now taking them to try to become the opposite sex.
“Blocking normal puberty has numerous unhealthy side effects including loss of normal bone development, interference with normal brain and social development, and importantly causes infertility and sexual dysfunction,” Laidlaw warns. “Many of these effects will be irreversible.”
Not only that, but this class of drugs is “very expensive,” he says. One 50mg subcutaneous implant of Supprellin LA, for example, costs $44,973. One parent who spoke to Laidlaw said a bill received from the hospital for the procedure and the medication device totaled around $210,000.
More related news about Big Pharma, gender dysphoria and puberty blocker drugs can be found at Gender.news.
Sources for this article include:
Tagged Under:
RECENT NEWS & ARTICLES
